Haemonetics stock performance snapshot after recent weakness Haemonetics (HAE) has drawn investor attention after a period of share price weakness, with the stock down about 9% over the past month and ...

Blood products company Haemonetics (NYSE:HAE). reported revenue ahead of Wall Street’s expectations in Q1 CY2026, with sales ...

Bank of America Global Healthcare Conference 2026 May 12, 2026 11:00 AM EDTCompany ParticipantsChristopher Simon - ...

Investors in Haemonetics Corporation HAE need to pay close attention to the stock based on moves in the options market lately. That is because the June 18, 2026 $40.00 Call had some of the highest ...

View Haemonetics Corporation HAE stock quote prices, financial information, real-time forecasts, and company news from CNN.

The most recent analyst rating on (HAE) stock is a Buy with a $70.00 price target. To see the full list of analyst forecasts on Haemonetics stock, see the HAE Stock Forecast page. According to Spark, ...

Haemonetics, which concentrates on hematology products and services, booked revenue of $327 million for the quarter. Although that was 5% down year over year, it handily topped the average analyst ...

Haemonetics (HAE) came out with quarterly earnings of $1.29 per share, beating the Zacks Consensus Estimate of $1.28 per share. This compares to earnings of $1.24 per share a year ago. These figures ...

BOSTON, Jan. 14, 2020 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative hematology solutions to drive better patient outcomes, ...